Overcoming current cancer treatment limitations by specifically addressing lymphatic and vascular angiogenesis via a single novel LVRF target
Designed from Kekkan’s proprietary translational target selection and antibody development platform, our lead program, Lyvepodimab, is a bispecific antibody against PD1 and a novel target, lymphatic and vascular endothelial resistance factor (LVRF) –a previously unaddressed driver of pathological angiogenesis and fibrosis. LVRF not only promotes both lymphangiogenesis and vascular angiogenesis but its expression is highly implicated in cancer progression, treatment resistance and poor prognosis.
Kekkan is advancing LyVePoDimab into the clinic for hard-to-treat cancers, initially targeting triple negative breast cancer (TNBC) as the lead indication. With a multimodal mechanism of action targeting both PD1 and LVRF, we are well-positioned to target metastatic cancers and fibrotic disorders through first-in-class biologics.